Why Crinetics Stock Doubled After Vertex’s $10 Billion Buyout

Crinetics Pharmaceuticals shares nearly doubled on Monday, July 6 after Vertex Pharmaceuticals agreed to buy the company for $10 billion in cash. Vertex will pay $85 a share. That is roughly double Crinetics closing price the day before Vertex announced the deal. What Vertex Is Actually Buying Crinetics makes Palsonify, a pill for acromegaly, a rare disorder that causes excess growth hormone. Patients previously relied on regular injections, so a once-daily pill is a real upgrade in convenience. Vertex, known for its cystic fibrosis drugs, is betting big on that convenience. It has a second drug in late-stage trials for another rare hormone condition. Together, the two products could bring in more than $5 billion a year at their peak. William Blair analyst Myles Minter said the price tag makes sense if that sales target holds up. Investors will debate this (stock was down 1.8% after hours), but we view this as reasonable if the peak sales number can be achieved. Crinetics saw a huge spike in a single day. Image Source: Trading View Retail sentiment on Crinetics flipped from bearish to bullish within a day. The GameStop eBay takeover saga shows how fast retail mood can swing on buyout news. Is There Any Upside Left? Once a company announces a cash buyout, its stock stops trading on its own business prospects. It trades toward the agreed price instead. Crinetics is already close to that $85 target. The Riot Platforms Bitfarms takeover played out the same way, with shares settling near the offer price. Most of the reward has already landed. What remains is a small gap, plus the risk that the deal falls through before it closes in the third quarter.